15.05
+0.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dr. Reddy’s Laboratories Ltd ADR
Its shares trade under the ticker RDY. It has been listed since 11 April 2001.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Apr 2001
- Website
- drreddys.com ↗
- Head office
- 8-2-337, ROAD NO.3 BANJARA HILLS, HYDERABAD, 500-034
- Incorporated in
- K7
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Dr. Reddy's Laboratories operates in key markets including North America, Europe, India, and Russia.
- The Global Generics segment provides prescription and over-the-counter pharmaceutical products with therapeutic equivalence.
- PSAI segment supplies active pharmaceutical ingredients and intermediates to the global market.
Weaknesses
- The company's business is concentrated in the Health Care sector.
- The PSAI segment focuses on active pharmaceutical ingredients without direct consumer engagement.
- The Others segment is developing therapies in oncology and inflammation without current commercialization.
Opportunities
- Expanding biologics business within the Global Generics segment.
- Growing demand for active pharmaceutical ingredients in the PSAI segment.
- Increasing focus on oncology and inflammation therapies in the Others segment.
Threats
- Regulatory challenges in the Health Care sector.
- Competition in the global generics market.
- Economic fluctuations affecting pharmaceutical demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.